3Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expre-ssion as a diagnostic marker for the earliest endometrial precanc-ers[J].J Natl Cancer Inst,2000,92(11):924-931.
4Mutter GL,Lin MC,Fitzgerald JT,et al.Changes in endometrial PTEN expression throughout the human menstrual cycle[J].J Clin Endocrinol Metab,2000,85(3):2334-2338.
6[8]Mutch DG,Soper JT,Budwit-Novotny DA,et al Endometrial adenocarcinoma estrogen receptor content: association of clinic pathologic features with immunahistochem icalanalysis compred with standard biochemical methods[J] AM J Obstet Gynecol,1987,157(4.partl):924.
7[10]CreasmanWT. Prognostic significance of receptors in endometrial cencer[J].Cancer,1993,71(4):1467.
8Garcia RL, Clotrera MD, Gown AM, et al. Analysis of proferating grade using anti-PCNA/cyclin monoclonal antibody in fixed embeded tissue:comparison with flow cytometric analysis. Am J Pathol, 1989, 134∶733-739.
9Berchuck A, Kohler MF, Hopkins MP, et al. Overexpression of p53 is not a feature of benign and earlier-stage borderline epithelial overian tumors. Gynecol Oncol, 1994, 52∶232-236.
10Niwa K, Murase T, Morishita S, et al. p53 overexpression and mutation in endometrial carcinoma:inverted relation with estrogen and progesterone receptor status. Cancer Delect Drev, 1999,23∶147-154.
10Oltrai Zn, Melliman CL, Korsmeyer SJ, et al. bcl-2 heterodimerizes in vivo with a consered homdog,bax, that accelerates progrmned cell death [J ]. Cell, 1993,74(4) : 609 - 619.
